Study on Olaparib and AZD6738 for Tumors with IDH1 and IDH2 Mutations

Inclusion Criteria

• Must understand the study and provide written consent. Patients with decision-making difficulties can participate if they have a caregiver or representative.
• Diagnosed with a solid tumor (not cholangiocarcinoma or primary brain tumor) that has worsened despite standard treatment or has no effective standard treatment.
• Tumors must have an IDH1 or IDH2 mutation confirmed by a certified lab.
• Tumors must be accessible for biopsy, and patients must agree to have biopsies taken.
• Must have measurable disease by standard criteria.
• Must have progressive cancer at the time of study entry.
• Must have recovered from previous treatments to a certain level of health.
• Must be 18 years or older.
• Must have good overall health and organ function as determined by specific medical tests.
• Women of childbearing potential must use effective contraception during and after the study.
• Men must agree to use contraception to prevent pregnancy in a partner during and after the study.
• Patients with HIV must have an undetectable viral load on treatment.

Exclusion Criteria

• Involvement in planning or conducting the study.
• Previous participation in this study.
• Participation in another study with an investigational product recently.
• Previous treatment with a PARP inhibitor or AZD6738.
• Recent chemotherapy or radiotherapy.
• Other cancers within the last 5 years, except for certain treated cancers.
• Uncontrolled heart conditions or certain medications that affect the heart.
• Severe allergies to study drugs.
• Major surgery recently.
• Serious uncontrolled medical conditions.
• Unable to swallow pills or have digestive issues affecting drug absorption.
• Pregnant or breastfeeding women.
• Recent blood transfusions.
• Receiving other investigational agents.